Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, aged 50 or older, memopausal.~* Meet DSM-IV criteria for current unipolar major depressive disorder.~* The total score of the HAMD-24 is at least 20 at screening and baseline.~* The current depressive episode within 1 year.~* If recurrent depression, the remission of previous episode is at least 5 years from the current episode.~* Providing informed consent form to participate in the study by patients or their legal representatives.~Exclusion Criteria:~* Current Axis I primary psychiatric diagnosis other than major depressive disorder.~* Substance abuse or dependence.~* Patients were also excluded if they had any medical condition that would contraindicate the use of venlafaxine or fluoxetine.~* Organic mental disease, including mental retardation.~* History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.~* Use of psychiatric agents within 5 days prior to randomization.~* Have proved no response to venlafaxin or fluoxetine by previous treatment.~* Participation in another clinical study within 4 weeks (or longer time according to the local requirement)~* Has received ECT or MECT within 3 months prior to randomization.~* Significant risk of suicidal and/or self-harm behaviors.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- venlafaxine (Type: ACTIVE_COMPARATOR): venlafaxine 75-225mg qd
- fluoxetine (Type: ACTIVE_COMPARATOR): fluoxetine 20-60mg qd

Based on this trial design, predict the completion outcome and termination type (if applicable).